On the design of the phase III drug trial. The example of rheumatoid arthritisHADLER, N. M; GILLINGS, D. B.Arthritis and rheumatism. 1983, Vol 26, Num 11, pp 1354-1361, issn 0004-3591Article

SELECTION OF APPROPRIATE STUDIES FOR PHASE III TRIALS OF RADIOSENSITIZERS = SELECTION DES ETUDES APPROPRIEES POUR LES ESSAIS EN PHASE II DES RADIOSENSIBILISATEURSMAOR MH; PETERS LJ.1983; INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS; ISSN 0360-3016; USA; DA. 1983; VOL. 9; NO 2; PP. 271; BIBL. 5 REF.Article

The ethical position of the attending physician in phase III of clinical investigationsVON EICKSTEDT, K.-W.International journal of clinical pharmacology, therapy and toxicology (1980). 1983, Vol 21, Num 10, pp 529-534, issn 0174-4879Article

Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanomaMARKOVIC, Svetomir; SUMAN, Vera J; KROOK, James E et al.American journal of clinical oncology. 2002, Vol 25, Num 6, pp 552-556, issn 0277-3732, 5 p.Article

MR angiography of aortoiliac occlusive disease : A phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325GOYEN, Mathias; EDELMAN, Mark; KENT YUCEL, E et al.Radiology. 2005, Vol 236, Num 3, pp 825-833, issn 0033-8419, 9 p.Article

What are the reasons for negative phase III trials of molecular-target-based drugs?SAIJO, Nagahiro.Cancer science. 2004, Vol 95, Num 10, pp 772-776, issn 1347-9032, 5 p.Article

Inference of Unexpected Genetic Relatedness among Individuals in HapMap Phase IIIPEMBERTON, Trevor J; CHAOLONG WANG; LI, Jun Z et al.American journal of human genetics. 2010, Vol 87, Num 4, pp 457-464, issn 0002-9297, 8 p.Article

The importance of reporting patient recruitment details in phase III trialsWRIGHT, James R; BOUMA, Sarah; DAYES, Ian et al.Journal of clinical oncology. 2006, Vol 24, Num 6, pp 843-847, issn 0732-183X, 5 p.Article

Fast recruiting clinical trials : a Utopian dream or logistical nightmare?JOHNSON, L; ELLIS, P; BLISS, Jm et al.British journal of cancer. 2005, Vol 92, Num 9, pp 1679-1683, issn 0007-0920, 5 p.Article

Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III studySZEIMIES, R.-M; RADNY, P; GAHLMANN, R et al.British journal of dermatology (1951). 2010, Vol 163, Num 2, pp 386-394, issn 0007-0963, 9 p.Article

Noninvasive assessment of airway alterations in smokers: The small airways revisitedVERBANCK, Sylvia; SCHUERMANS, Daniël; MEYSMAN, Marc et al.American journal of respiratory and critical care medicine. 2004, Vol 170, Num 4, pp 414-419, issn 1073-449X, 6 p.Article

New data on MAGE-A3 cancer immunotherapy may signal new options for patients with melanoma and non-small cell lung cancer = Immunisation active contre MAGE-a3: vers une nouvelle option thérapeutique dans le cancer du poumon et le mélanomeBRICHARD, V. G; LEJEUNE, D.Revue des maladies respiratoires actualités (Print). 2010, Vol 2, Num 3, pp 282-285, issn 1877-1203, 4 p.Conference Paper

A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabineCIULEANU, Tudor E; PAVLOVSKY, Alexander V; BODOKY, Gyorgy et al.European journal of cancer (1990). 2009, Vol 45, Num 9, pp 1589-1596, issn 0959-8049, 8 p.Article

Disclosure of competing financial interests and role of sponsors in phase III cancer trialsTUECH, Jean-Jacques; MOUTEL, Grégoire; PESSAUX, Patrick et al.European journal of cancer (1990). 2005, Vol 41, Num 15, pp 2237-2240, issn 0959-8049, 4 p.Article

Phase III Clinical Trial Development: A Process of Chutes and LaddersDILTS, David M; CHENG, Steven K; CRITES, Joshua S et al.Clinical cancer research (Print). 2010, Vol 16, Num 22, pp 5381-5389, issn 1078-0432, 9 p.Article

Using a drug before the risks and benefits are known from a phase 3 clinical trial : Thoughts on compassionMILLER, Joan W.Archives of ophthalmology (1960). 2006, Vol 124, Num 7, pp 1029-1031, issn 0003-9950, 3 p.Article

Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007KORN, Edward L; FREIDLIN, Boris; MOONEY, Margaret et al.Journal of clinical oncology. 2010, Vol 28, Num 35, pp 5197-5201, issn 0732-183X, 5 p.Article

The benefits of participation in clinical trialsVAN DONGEN, J. A; VAN DE VELDE, C. J. H.European journal of surgical oncology. 1996, Vol 22, Num 6, pp 561-562, issn 0748-7983Article

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MSFREEDMAN, M. S; BAR-OR, A; FERENCZI, L et al.Neurology. 2011, Vol 77, Num 16, pp 1551-1560, issn 0028-3878, 10 p.Article

Phase III Clinical Trials That Integrate Treatment and Biomarker EvaluationFREIDLIN, Boris; ZHUOXIN SUN; GRAY, Robert et al.Journal of clinical oncology. 2013, Vol 31, Num 25, pp 3158-3161, issn 0732-183X, 4 p.Article

Time to mandate data release and independent audits for all clinical trialsHAINES, Ian E; GABOR MIKLOS, George L.Medical journal of Australia. 2011, Vol 195, Num 10, pp 575-577, issn 0025-729X, 3 p.Article

Responsiveness of NEI VFQ-25 to Changes in Visual Acuity in Neovascular AMD: Validation Studies from Two Phase 3 Clinical TrialsSUNER, Ivan J; KOKAME, Gregg T; YU, Elaine et al.Investigative ophthalmology & visual science. 2009, Vol 50, Num 8, pp 3629-3635, issn 0146-0404, 7 p.Article

Peut-on prédire la bonne posologie de la phase III ? = Ho<w to predict the therapeutic dose range to be tested in phase III clinical trials?DAHAN, R; JAILLON, P; LEHNER, J. P et al.Thérapie (Paris). 1993, Vol 48, Num 4, pp 297-301, issn 0040-5957Conference Paper

PIPERACILLIN SODIUM (A PHASE III CLINICAL TRIAL)MACBETH WAAG.1981; J. INT. MED. RES.; ISSN 0300-0605; GBR; DA. 1981; VOL. 9; NO 5; PP. 353-359; BIBL. 1 REF.Article

Enzalutamide for the treatment of prostate cancerPAL, Sumanta K; STEIN, Cy A; SARTOR, Oliver et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 5, pp 679-685, issn 1465-6566, 7 p.Article